To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

How to transfigure the Wikipedia

Would you like Wikipedia to always look as professional and up-to-date? We have created a browser extension. It will enhance any encyclopedic page you visit with the magic of the WIKI 2 technology.

Try it — you can delete it anytime.

Install in 5 seconds
4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
Great Wikipedia has got greater.
.
Leo
Newton
Brights
Milds

Azemiglitazone

From Wikipedia, the free encyclopedia

Azemiglitazone
Clinical data
Other namesAzemiglitazone potassium; MSDC-0602; MSDC-0602K
Legal status
Legal status
  • Investigational
Identifiers
  • 5-[[4-[2-(3-Methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC19H17NO5S
Molar mass371.41 g·mol−1
3D model (JSmol)
  • COC1=CC=CC(=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
  • InChI=1S/C19H17NO5S/c1-24-15-4-2-3-13(10-15)16(21)11-25-14-7-5-12(6-8-14)9-17-18(22)20-19(23)26-17/h2-8,10,17H,9,11H2,1H3,(H,20,22,23)
  • Key:YAUMOGALQJYOJQ-UHFFFAOYSA-N

Azemiglitazone (MSDC-0602) is a novel insulin sensitizer designed to retain the effect of thiazolidinediones on mitochondrial pyruvate carriers with limited PPAR-gamma binding. It is hoped to have fewer adverse effects than the thiazolidinediones and is being developed by Cirius Therapeutics for type 2 diabetes and non-alcoholic fatty liver disease.[1][2][3] It is formulated as its potassium salt, azemiglitazone potassium (MSDC-0602K).

References

  1. ^ Colca, Jerry R.; Lee, Bo Hyun; Iwashita, Julie S.; Dittrich, Howard C.; Harrison, Stephen A. (1 June 2020). "1090-P: MSDC-0602k, a New Oral Insulin Sensitizer in Insulin Resistant NASH Patients with and without Type 2 Diabetes (T2D)". Diabetes. 69 (Supplement_1). doi:10.2337/db20-1090-P. S2CID 225824217.
  2. ^ Harrison, Stephen A.; Alkhouri, Naim; Davison, Beth A.; Sanyal, Arun; Edwards, Christopher; Colca, Jerry R.; Lee, Bo Hyun; Loomba, Rohit; Cusi, Kenneth; Kolterman, Orville; Cotter, Gad; Dittrich, Howard C. (April 2020). "Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study". Journal of Hepatology. 72 (4): 613–626. doi:10.1016/j.jhep.2019.10.023. PMID 31697972.
  3. ^ Kamm, Dakota R.; Pyles, Kelly D.; Sharpe, Martin C.; Healy, Laura N.; Colca, Jerry R.; McCommis, Kyle S. (January 2021). "Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide". Journal of Biological Chemistry. 296: 100807. doi:10.1016/j.jbc.2021.100807. PMC 8192871. PMID 34022222.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

This page was last edited on 30 April 2024, at 12:16
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.
Contact WIKI 2
Introduction
Terms of Service
Privacy Policy